Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

YKL-40 is a glycoprotein with pro-angiogenic functions. We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab. Plasma samples were collected from 563 patients in the randomized, phase 3 AVAglio trial w...

Descripción completa

Detalles Bibliográficos
Autores principales: Boisen, Mogens K., Holst, Camilla B., Consalvo, Nicola, Chinot, Olivier L., Johansen, Julia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805511/
https://www.ncbi.nlm.nih.gov/pubmed/29467925
http://dx.doi.org/10.18632/oncotarget.22886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805511/
https://www.ncbi.nlm.nih.gov/pubmed/29467925
http://dx.doi.org/10.18632/oncotarget.22886

Ejemplares similares